Profile data is unavailable for this security.
About the company
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
- Revenue in USD (TTM)15.18k
- Net income in USD-13.77m
- Incorporated1994
- Employees12.00
- LocationKazia Therapeutics LtdThree International Towers Level 24, 300 Barangaroo AvenueSYDNEY 2000AustraliaAUS
- Phone+61 29472-4100
- Fax+61 29476-0388
- Websitehttps://www.kaziatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HST Global Inc | 0.00 | -141.11k | 5.72m | 1.00 | -- | -- | -- | -- | -0.0269 | -0.0269 | 0.00 | -0.1193 | 0.00 | -- | -- | -- | -29,397.92 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -24.24 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 2.83m | -10.03m | 5.74m | 17.00 | -- | 0.4816 | -- | 2.03 | -64.14 | -64.14 | 4.60 | 3.82 | 0.2041 | 2.69 | 7.77 | 166,299.40 | -72.67 | -80.65 | -107.67 | -224.84 | 23.33 | -- | -356.09 | -948.54 | 1.87 | -- | 0.0451 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -17.06m | 5.75m | 10.00 | -- | 1.10 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.44m | -4.47m | 5.77m | 4.00 | -- | 0.6648 | -- | 2.36 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 5.81m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.34m | 5.83m | 2.00 | -- | -- | -- | -- | -0.0102 | -0.0102 | 0.00 | -0.0002 | 0.00 | -- | -- | -- | -62,992.45 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -33.94m | 5.85m | 25.00 | -- | 0.4868 | -- | -- | -303.31 | -303.31 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Ainos Inc | 93.68k | -14.56m | 5.91m | 46.00 | -- | 0.2547 | -- | 63.06 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.95m | 6.11m | 1.00 | -- | 0.568 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.23m | 5.00 | -- | 0.501 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 15.18k | -13.77m | 6.29m | 12.00 | -- | 0.5936 | -- | 414.27 | -0.835 | -0.835 | 0.0008 | 0.3555 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 6.38m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.89m | 6.39m | 21.00 | -- | 0.2686 | -- | -- | -1.26 | -1.26 | 0.00 | 0.3388 | 0.00 | -- | -- | 0.00 | -168.89 | -132.00 | -228.29 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 6.66m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Kineta Inc | 5.16m | -17.89m | 6.88m | 11.00 | -- | -- | -- | 1.33 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 6.91m | 75.00 | 0.0003 | 0.00002 | 1.28 | 0.3881 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
Data as of Jul 03 2024. Currency figures normalised to Kazia Therapeutics Ltd's reporting currency: US Dollar USD
1.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 197.85k | 0.70% |
| HSBC Bank Plc (Broker)as of 31 Mar 2024 | 63.96k | 0.23% |
| BNP Paribas Financial Marketsas of 31 Mar 2024 | 48.60k | 0.17% |
| XTX Markets LLCas of 31 Mar 2024 | 18.49k | 0.07% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 18.42k | 0.07% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 12.17k | 0.04% |
| Ground Swell Capital LLCas of 31 Mar 2024 | 11.15k | 0.04% |
| Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 500.00 | 0.00% |
| Allworth Financial LPas of 31 Mar 2024 | 87.00 | 0.00% |
| AdvisorNet Financial, Inc.as of 31 Mar 2024 | 5.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
